Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of the Safety and Activity of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis

NCT00428974 is registered in ClinicalTrials.gov with Can-Fite BioPharma as lead sponsor.

NCT NCT00428974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00428974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of the Safety and Activity of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis
Lead sponsor
Can-Fite BioPharma
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2007
Completion date
September 30, 2009
Enrollment
76 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis